NTLA Q3 2017 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+50.3% YoY

Gross Profit

-$10M-138.9% margin

Operating Income

-$16M-217.0% margin

Net Income

-$15M-209.9% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+23.7%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$19M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$249M

Total Liabilities

$73M

Stockholders' Equity

$176M

Cash & Equivalents

$222M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$5M	+50.3%
Gross Profit	-$10M	-$3M	-239.7%
Operating Income	-$16M	-$8M	-106.2%
Net Income	-$15M	-$7M	-105.2%